The FDA has updated some information about the December recall of certain Abbott FreeStyle Libre 3 and 3 Plus glucose sensors ...
The U.S. Food and Drug Administration (FDA) is issuing an Early Alert for specific glucose monitoring systems after Abbott ...
Abbott Diabetes Care has recalled some of its FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitor sensors for people ...
Abbott Diabetes Care recalled FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors due to defective readings that show lower ...
The Food and Drug Administration has identified a Class I recall of certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus ...
Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.
Abbott Laboratories (NYSE:ABT) received an FDA warning letter focused on the accuracy and testing of its FreeStyle Libre ...
Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin (HbA1c) at three months 1 Reductions in HbA1c ...
ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the ...
Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...
Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people 3 and often accompanied by cardiovascular complications. 4 People with Type 1 and Type 2 diabetes are 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results